Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean L Chan

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
The Journal of Clinical Endocrinology and Metabolism|May 1, 2008
Leptin does not mediate short-term fasting-induced changes in growth hormone pulsatility but increases IGF-I in leptin deficiency statesJean L Chan, Catherine J Williams, Patricia Raciti, et al.
Leukemia & Lymphoma|April 14, 2015
Lymphoma in acquired generalized lipodystrophyRebecca J Brown, Jean L Chan, Elaine S Jaffe, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 23, 2006
Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humansJean L Chan, Giuseppe Matarese, Greeshma K Shetty, et al.
European Journal of Endocrinology|November 26, 2008
r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humansAoife M Brennan, Jennifer H Lee, Sotirios Tsiodras, et al.
The Journal of Clinical Endocrinology and Metabolism|October 15, 2021
Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal HyperplasiaRichard J Auchus, Kyriakie Sarafoglou, Patricia Y Fechner, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|November 9, 2020
Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C-Treated Liver Transplant Recipients With Residual Fibrosis or CirrhosisEthan M Weinberg, Michael P Curry, Catherine T Frenette, et al.
The Journal of Clinical Endocrinology and Metabolism|May 22, 2023
Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal HyperplasiaRon S Newfield, Kyriakie Sarafoglou, Patricia Y Fechner, et al.
Journal of Hepatology|October 10, 2020
Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosisCatherine Frenette, Zeid Kayali, Edward Mena, et al.
Hepatology (Baltimore, Md.)|August 1, 2018
Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal HypertensionGuadalupe Garcia-Tsao, Michael Fuchs, Mitchell Shiffman, et al.
Journal of Hepatology|December 25, 2019
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertensionGuadalupe Garcia-Tsao, Jaime Bosch, Zeid Kayali, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
The Journal of Clinical Endocrinology and Metabolism|May 1, 2008
Leptin does not mediate short-term fasting-induced changes in growth hormone pulsatility but increases IGF-I in leptin deficiency statesJean L Chan, Catherine J Williams, Patricia Raciti, et al.
Leukemia & Lymphoma|April 14, 2015
Lymphoma in acquired generalized lipodystrophyRebecca J Brown, Jean L Chan, Elaine S Jaffe, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 23, 2006
Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humansJean L Chan, Giuseppe Matarese, Greeshma K Shetty, et al.
European Journal of Endocrinology|November 26, 2008
r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humansAoife M Brennan, Jennifer H Lee, Sotirios Tsiodras, et al.
The Journal of Clinical Endocrinology and Metabolism|October 15, 2021
Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal HyperplasiaRichard J Auchus, Kyriakie Sarafoglou, Patricia Y Fechner, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|November 9, 2020
Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C-Treated Liver Transplant Recipients With Residual Fibrosis or CirrhosisEthan M Weinberg, Michael P Curry, Catherine T Frenette, et al.
The Journal of Clinical Endocrinology and Metabolism|May 22, 2023
Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal HyperplasiaRon S Newfield, Kyriakie Sarafoglou, Patricia Y Fechner, et al.
Journal of Hepatology|October 10, 2020
Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosisCatherine Frenette, Zeid Kayali, Edward Mena, et al.
Hepatology (Baltimore, Md.)|August 1, 2018
Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal HypertensionGuadalupe Garcia-Tsao, Michael Fuchs, Mitchell Shiffman, et al.
Journal of Hepatology|December 25, 2019
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertensionGuadalupe Garcia-Tsao, Jaime Bosch, Zeid Kayali, et al.
Pageof 5